Integra LifeSciences IART Cash Flow Statement
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| -$495.8M+4.0% | -$516.47M— | —— | —— | —— | ||
| $153.07M+0.8% | $151.83M+0.6% | $150.99M+1.7% | $148.43M+0.6% | $147.52M+4.7% | ||
| $21.88M+17.7% | $18.58M-6.6% | $19.9M+6.4% | $18.7M-9.4% | $20.65M-15.3% | ||
| -$63.11M+4.8% | -$66.26M-6.4% | -$62.3M+0.6% | -$62.69M-218% | -$19.71M+4.9% | ||
| —— | —— | —— | —— | -$483K— | ||
| $8.29M+1,609% | $485K— | —— | —— | —— | ||
| $37.39M-20.0% | $46.76M+6.3% | $43.99M+42.2% | $30.95M+26.0% | $24.57M-17.8% | ||
| $25.54M-4.4% | $26.72M+1,714% | -$1.66M-171% | -$612K— | —— | ||
| —— | —— | —— | —— | —— | ||
| -$18.18M-5.9% | -$17.16M-697% | $2.88M-66.1% | $8.47M+1,529% | -$593K-538% | ||
| $2.53M-25.7% | $3.4M-23.3% | $4.43M+9.1% | $4.06M-27.8% | $5.63M+44.8% | ||
| -$22.46M-5.3% | -$21.33M-6.0% | -$20.12M-158% | -$7.8M-21.7% | -$6.41M-10.7% | ||
| $71.44M+41.8% | $50.38M-43.6% | $89.31M+26.0% | $70.89M-30.8% | $102.37M-20.9% | ||
| $67.36M-17.3% | $81.44M-13.2% | $93.82M-13.4% | $108.31M-8.1% | $117.87M+12.9% | ||
| —— | —— | —— | —— | —— | ||
| -$86.99M+19.5% | -$108.06M-39.6% | -$77.41M-7.2% | -$72.21M+80.6% | -$372.76M+4.6% | ||
| $1.94M-28.2% | $2.7M0.0% | $2.7M+1.0% | $2.67M+5.7% | $2.52M-28.1% | ||
| —— | —— | —— | —— | —— | ||
| —— | —— | —— | —— | —— | ||
| $12.8M-32.0% | $18.82M+107% | $9.08M-46.0% | $16.83M+456% | $3.03M+147% | ||
| —— | —— | —— | —— | —— | ||
| $5.22M-7.0% | $5.61M-6.4% | $5.99M-0.3% | $6.01M+7.7% | $5.58M-0.2% | ||
| -$22.46M-5.3% | -$21.33M-6.0% | -$20.12M-158% | -$7.8M-21.7% | -$6.41M-10.7% | ||
| -$18.18M-5.9% | -$17.16M-697% | $2.88M-66.1% | $8.47M+1,529% | -$593K-538% | ||
| -$3.22M+3.7% | -$3.34M-49.4% | -$2.24M-122% | $10.03M+500% | $1.67M-41.2% | ||
| —— | —— | —— | —— | —— | ||
| —— | $1.3M-57.9% | $3.09M-36.7% | $4.88M-26.8% | $6.66M-21.2% | ||
| —— | —— | —— | —— | —— | ||
| $153.07M+0.8% | $151.83M+0.6% | $150.99M+1.7% | $148.43M+0.6% | $147.52M+4.7% | ||
| —— | —— | —— | —— | —— | ||
| $115.25M+21.4% | $94.91M-13.5% | $109.76M-2.5% | $112.62M-39.9% | $187.28M+0.1% | ||
| $2.53M-25.7% | $3.4M-23.3% | $4.43M+9.1% | $4.06M-27.8% | $5.63M+44.8% | ||
| —— | —— | —— | —— | —— | ||
| $710.8M-1.4% | $720.7M+2.0% | $706.4M+467% | $124.5M-26.9% | $170.4M-65.0% | ||
| —— | —— | —— | —— | —— |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How much cash does Integra LifeSciences generate?
- Integra LifeSciences (IART) generated $71.4M in operating cash flow over the trailing twelve months.
- What is Integra LifeSciences's free cash flow?
- After $67.4M of capital expenditures, Integra LifeSciences's free cash flow was -$61.8M over the trailing twelve months, down 193.2% year over year.
- Where does Integra LifeSciences's cash flow data come from?
- Every line is extracted from Integra LifeSciences's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
